Literature DB >> 15866072

Characterization of neutralizing antibodies to West Nile virus.

Melissa D Sánchez1, Theodore C Pierson, Douglas McAllister, Sheri L Hanna, Bridget A Puffer, Laura E Valentine, Mariam M Murtadha, James A Hoxie, Robert W Doms.   

Abstract

We produced nine monoclonal antibodies (MAbs) directed against the West Nile virus E glycoprotein using three different immunization strategies: inactivated virus, naked DNA, and recombinant protein. Most of the MAbs bound to conformation dependent epitopes in domain III of the E protein. Four of the MAbs neutralized WNV infection and bound to the same region of domain III with high affinity. The neutralizing MAbs were obtained from mice immunized with inactivated virus alone or in combination with a DNA plasmid. In contrast, MAbs obtained by immunization with a soluble version of the E glycoprotein did not exhibit neutralizing activity. These non-neutralizing antibodies were cross-reactive with several other flaviviruses, including Saint Louis encephalitis, Japanese encephalitis, Yellow Fever and Powassan viruses. Interestingly, some non-neutralizing MAbs bound with high affinity to domains I or III, indicating that both affinity and the precise epitope recognized by an antibody are important determinants of WNV neutralization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866072     DOI: 10.1016/j.virol.2005.02.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  65 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.

Authors:  Ryuta Kanai; Kalipada Kar; Karen Anthony; L Hannah Gould; Michel Ledizet; Erol Fikrig; Wayne A Marasco; Raymond A Koski; Yorgo Modis
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.

Authors:  Carl W Davis; Hai-Yen Nguyen; Sheri L Hanna; Melissa D Sánchez; Robert W Doms; Theodore C Pierson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation.

Authors:  Camilo Ansarah-Sobrinho; Steevenson Nelson; Christiane A Jost; Stephen S Whitehead; Theodore C Pierson
Journal:  Virology       Date:  2008-09-17       Impact factor: 3.616

Review 5.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

6.  Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.

Authors:  Serafeim C Chaintoutis; Nikolaos Diakakis; Maria Papanastassopoulou; Georgios Banos; Chrysostomos I Dovas
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

7.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

10.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.